BTIG Research initiated coverage on Spectral AI with a new price target
$MDAI
Medical/Dental Instruments
Health Care
BTIG Research initiated coverage of Spectral AI with a rating of Buy and set a new price target of $4.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/23/2024 | $4.00 | Buy | BTIG Research |
4 - Spectral AI, Inc. (0001833498) (Issuer)
4 - Spectral AI, Inc. (0001833498) (Issuer)
4 - Spectral AI, Inc. (0001833498) (Issuer)
4 - Spectral AI, Inc. (0001833498) (Issuer)
2024 Research & Development Revenue of $30 Million Successful Results from the US Burn Validation Study On Track for Regulatory Submission in US for DeepView™ System DALLAS, March 27, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence ("AI") company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the fourth quarter ("Q4 2024") and full year ("FY 2024") ended December 31, 2024, and provided an update on its ongoing business activities. "Spectral AI achieved much in 2024. Our top-l
DALLAS, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ:MDAI) ("Spectral AI" or the "Company"), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration ("FDA") in 2018 and uses multi-spectral imaging and AI algorithms to predict burn healing potential, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024 on Wednesday, March 27, 2025 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time to discuss the results. Investors interested in participating in the live call can dial: 844-481-30
Revenue Rose to $8.2 MillionCompany Reaffirms Timeline for Regulatory Submission to U.S. FDA Q3 2024 Overview Research & Development Revenue Rose 138% to $8.2 MillionLast Patient Out at Burn Centers for U.S. Burn Pivotal Study; Top Line Study Results Expected in Q4 2024U.S. FDA Submission on Track for Q2 2025Completed Proof-of-Concept Module for Wound Measurement Technology DALLAS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the third quarter ended S
Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, April 2, 2025 /PRNewswire/ -- Equity Insider News Commentary – Artificial Intelligence (AI) is quickly becoming a major force in healthcare, as use of AI applications in medical fields is growing rapidly. Researchers at Dartmouth recently conducted the first clinical trial of a therapy chatbot powered by generative AI (genAI), and found that it resulted in significant improvements in participants' symptoms. Cleveland Clinic and UAE-based G42 recently started collaborating on the advancement of even more AI in healthcare adoption, signalling an international push in this revolution. Because of this, the
2024 Research & Development Revenue of $30 Million Successful Results from the US Burn Validation Study On Track for Regulatory Submission in US for DeepView™ System DALLAS, March 27, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence ("AI") company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the fourth quarter ("Q4 2024") and full year ("FY 2024") ended December 31, 2024, and provided an update on its ongoing business activities. "Spectral AI achieved much in 2024. Our top-l
DALLAS, March 24, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), a leading developer of the AI-driven DeepView® System, which uses multi-spectral imaging and AI algorithms to predict burn healing potential, today announced the successful completion of a debt financing agreement of up to $15.0 million in funding from Avenue Venture Opportunities Fund II, L.P., a fund of Avenue Capital Group, with an initial draw down of $8.5 million. In connection with this debt financing, the Company also raised $2.7 million of equity financing from institutional as well as existing investors. With total cash on hand now of over $14 million and potential access t
DALLAS, May 29, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it is set to join the Russell Microcap® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective following the closing of US equity markets on Friday, June 28, 2024 according to a preliminary list of additions posted Friday, May 24, 2024. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, 2024 ranking them by total market capitalization. Members
DALLAS, May 15, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced results from its 2024 Annual Meeting of Stockholders held on May 14, 2024 (the "AGM"). At the AGM, stockholders overwhelmingly approved each of the four proposals set forth by the Company. The voting results are detailed below. Six directors were elected to serve until the next Annual Meeting of Stockholders: Richard Cotton, Chairman of the Company's Board of DirectorsPeter M. Carlson, Chief Executive Officer of the
DALLAS, April 01, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of Jeremiah A. Sparks as Chief Commercialization Officer. Jeremiah has more than 20 years of medical device marketing experience, including global marketing and business strategy. Mr. Sparks will be responsible for both domestic and international product commercialization. "We are thrilled to have Jeremiah join the company as we move towards commercialization of DeepView," said Peter M. Carlson, CEO of Spectral AI.
BTIG Research initiated coverage of Spectral AI with a rating of Buy and set a new price target of $4.00
S-3 - Spectral AI, Inc. (0001833498) (Filer)
DEFA14A - Spectral AI, Inc. (0001833498) (Filer)
DEF 14A - Spectral AI, Inc. (0001833498) (Filer)
SC 13G/A - Spectral AI, Inc. (0001833498) (Subject)
SC 13G/A - Spectral AI, Inc. (0001833498) (Subject)
SC 13D/A - Spectral AI, Inc. (0001833498) (Subject)